24/7 Clients Support
- 24/7
Customer Service
- ISO 9001
Certification Company
- WHO-GMP
Certified Company
BENDALIEVA 100MG is an Injection medication used for treatment purposes. It is manufactured by Allieva Pharma Private Limited.
| Brand Name | BENDALIEVA 100MG |
|---|---|
| Composition | Bendamustine Hydrochloride for Injection 100mg |
| Manufacturer | Allieva Pharma Private Limited |
| Dosage Form | Injection |
| Packaging | Vial |
| Country of Origin | India |
BENDALIEVA 100MG (Bendamustine Hydrochloride for Injection 100mg) is a widely used Injection medicine manufactured by Allieva Pharma Private Limited. It is commonly prescribed for...
BENDALIEVA 100 MG (Bendamustine Hydrochloride for Injection 100 mg) is a prescription anticancer medicine used in the treatment of various hematological malignancies, including Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin Lymphoma (NHL), and certain other blood-related cancers. It contains Bendamustine Hydrochloride 100 mg, a potent chemotherapy agent that combines the properties of an alkylating agent and an antimetabolite, helping to destroy cancer cells and slow disease progression.
Blood cancers develop when abnormal white blood cells grow uncontrollably and interfere with the body's ability to produce healthy blood cells. These abnormal cells can accumulate in the bone marrow, lymph nodes, spleen, and bloodstream, affecting normal immune function and overall health. BENDALIEVA 100 MG is specifically designed to target these rapidly dividing cancer cells and help control their growth.
Bendamustine works by damaging the DNA of cancer cells, preventing them from replicating and surviving. Unlike some traditional chemotherapy medicines, Bendamustine has a unique chemical structure that enables it to attack cancer cells through multiple mechanisms. This makes it an important treatment option for patients with certain blood cancers, including those who may not respond adequately to other therapies.
BENDALIEVA 100 MG is commonly prescribed for:
The medicine may be used alone or in combination with other anticancer therapies depending on the patient's diagnosis, treatment history, and clinical condition.
Manufactured under stringent pharmaceutical quality standards, BENDALIEVA 100 MG is designed to provide consistent therapeutic effectiveness, safety, and reliability. The injection should only be administered by qualified healthcare professionals experienced in oncology and hematology treatment.
Patients receiving Bendamustine therapy often require regular blood tests, liver and kidney function monitoring, infection screening, and routine clinical evaluations to ensure safe and effective treatment.
Due to its established effectiveness in managing blood cancers, BENDALIEVA 100 MG remains an important component of modern cancer treatment protocols worldwide.
BENDALIEVA 100 MG (Bendamustine Hydrochloride for Injection 100 mg) is primarily used for the treatment and management of blood cancers and lymphatic system malignancies.
The medicine is widely used in the treatment of chronic lymphocytic leukemia to help control abnormal white blood cell growth.
Bendamustine is commonly prescribed for certain types of non-Hodgkin lymphoma.
The medicine may be used in patients with slow-growing B-cell lymphomas.
Doctors may prescribe Bendamustine for lymphoma that has returned after previous treatment.
The medicine may be considered when certain blood cancers do not respond adequately to standard therapies.
BENDALIEVA is frequently used alongside other anticancer medicines to improve treatment outcomes.
The medicine supports comprehensive treatment strategies for complex hematological malignancies.
Bendamustine belongs to a class of medicines known as Alkylating Agents.
BENDALIEVA works by:
Its dual-action properties make it particularly effective in treating certain blood cancers and lymphomas.
Like all chemotherapy medicines, BENDALIEVA 100 MG may cause side effects in some patients. Side effects vary depending on dosage, treatment duration, and individual response.
Weakness and tiredness are commonly reported during treatment.
Patients may experience mild to moderate nausea.
Episodes of vomiting may occur after administration.
Mild fever may develop during therapy.
Reduced appetite may affect nutritional intake.
Some patients may experience digestive discomfort and constipation.
Loose stools and gastrointestinal disturbances may occur.
Mild skin reactions may develop in some individuals.
The medicine may reduce:
This may increase the risk of infections, anemia, and bleeding complications.
Seek immediate medical attention if you experience:
Patients should immediately contact their healthcare provider if serious symptoms occur.
The dosage of BENDALIEVA 100 MG (Bendamustine Hydrochloride for Injection 100 mg) should always be determined by a qualified oncologist or hematologist.
Treatment schedules vary according to the diagnosed condition.
Dosage is commonly calculated according to body size.
Laboratory results play a major role in determining treatment suitability.
Organ function may influence treatment planning and dosage adjustments.
Doctors may modify therapy based on effectiveness and patient tolerance.
Before receiving treatment, patients should inform their doctor if they have:
Patients should also disclose all prescription medicines, supplements, and herbal products they are currently taking to avoid potential drug interactions.
Pregnant or breastfeeding women should only receive this medicine if specifically recommended by a healthcare professional.
It is primarily used for the treatment of Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin Lymphoma (NHL), and related blood cancers.
Bendamustine Hydrochloride is a chemotherapy medicine that damages cancer cell DNA and helps prevent cancer cell growth and replication.
Yes, it is a widely used chemotherapy medicine for hematological malignancies and lymphoma treatment.
Yes, it is frequently administered as part of combination treatment regimens.
Yes, the medicine may lower blood cell counts, requiring regular laboratory monitoring.
Yes, reduced white blood cell counts may increase susceptibility to infections during treatment.
Yes, doctors typically recommend blood tests, liver and kidney assessments, and routine clinical evaluations throughout therapy.
Yes, this medicine should only be administered by qualified healthcare professionals experienced in oncology, hematology, and specialized cancer treatment.